GLP-1 receptor agonists
Nutrient-stimulated hormone agonists (GLP-1 RAs and the dual GIP/GLP-1 RA tirzepatide) delivering potent A1C reduction, substantial weight loss, negligible intrinsic hypoglycaemia, and proven ASCVD, CKD, HFpEF, OSA, and MASH benefits (agent-specific). Contraindicated in medullary thyroid carcinoma / MEN2 and pregnancy.
Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2 (rodent C-cell tumour boxed warning).
mechanism
Activate GLP-1 receptors (and GIP receptors for tirzepatide) → glucose-dependent insulin secretion, suppressed postprandial glucagon, slowed gastric emptying, and central hypothalamic satiety signalling.
comparison and dosing
Titrate slowly every 4 weeks to limit nausea/vomiting. No dose adjustment down to eGFR 15 mL/min/1.73 m² (limited data <15 or on dialysis).
| agent | route & schedule | T2DM max dose | obesity dose | proven organ-outcome benefits |
|---|---|---|---|---|
| semaglutide (Ozempic / Wegovy / Rybelsus) | SC weekly (or PO daily) | 2 mg SC weekly (14 mg PO daily) | 2.4 mg SC weekly | MACE in T2DM (SC) and non-diabetic ASCVD + BMI ≥27 (2.4 mg); CKD progression & CV death in T2DM (1 mg); HFpEF symptoms/events (2.4 mg); MASH resolution & fibrosis; knee OA pain |
| tirzepatide (Mounjaro / Zepbound) | SC weekly (dual GIP/GLP-1) | 15 mg weekly | 5, 10, or 15 mg weekly | largest A1C and weight loss (~15–21%); HFpEF CV death/worsening HF (15 mg); moderate–severe OSA (10–15 mg); MASH; dedicated T2DM CVOT/CKD trials pending |
| liraglutide (Victoza / Saxenda) | SC daily | 1.8 mg daily | 3 mg daily | MACE & CV mortality in T2DM; prediabetes progression; OSA (3 mg). Avoid in acute HFrEF (↑ HF events) |
| dulaglutide (Trulicity) | SC weekly | 4.5 mg weekly | T2DM only | MACE (primary + secondary CV prevention in T2DM), ↓ stroke |
- Avoid exenatide and lixisenatide when cardiorenal protection is the goal — neutral for MACE. Oral semaglutide lacks proven cardiorenal superiority in Diabetes Canada 2024 (take fasting with ≤120 mL water, wait ≥30 min before food/meds).
key points
- Do not combine with DPP-4 inhibitors (redundant mechanism; stop DPP-4i when starting a GLP-1 RA or tirzepatide).
- Concomitant sulfonylurea or insulin: intrinsic hypoglycaemia risk is negligible, so reduce sulfonylurea or insulin doses when adding a GLP-1 RA to avoid lows.
- Weight regain on stopping: obesity trials consistently show regain of weight and loss of cardiometabolic benefit after discontinuation → treat as long-term chronic therapy (obesity).
- Diabetic retinopathy: rapid A1C lowering (notably SC semaglutide) can transiently worsen pre-existing proliferative retinopathy → ensure baseline dilated eye exam and close monitoring in high-risk patients.
- Pregnancy & contraception: avoid in pregnancy; counsel on reliable contraception and stop before planned conception. Tirzepatide reduces oral contraceptive absorption via delayed gastric emptying — use non-oral or backup contraception for 4 weeks after initiation and each dose escalation (ADA 2026).
- Do not use compounded products: Obesity Canada 2025 and ADA 2026 recommend against non-approved compounded formulations.
- Ontario: ODB covers SC semaglutide (Ozempic) under LU 665–667 and oral semaglutide (Rybelsus) under LU 662–664 / 738–740 for T2DM inadequately controlled on max tolerated metformin; Wegovy, Saxenda, and tirzepatide are not ODB-covered.
adverse effects
- GI (most common, dose-dependent, improves with slow titration): nausea, vomiting, diarrhoea, constipation, dyspepsia, delayed gastric emptying (aspiration/ileus caution; avoid in severe gastroparesis).
- Gallbladder disease: cholelithiasis and cholecystitis (rapid weight loss + reduced gallbladder motility).
- Pancreatitis: caution with prior pancreatitis; discontinue if suspected (large RCTs show no clear excess risk).
- Retinopathy worsening: associated with rapid A1C drop in established retinopathy.
- MTC / MEN2: contraindicated (boxed warning).
evidence
- SUSTAIN-6 / SELECT / FLOW / STEP-HFpEF: SC semaglutide lowers MACE in T2DM and non-diabetic ASCVD + obesity, reduces kidney failure and CV death in T2DM-CKD, and improves HFpEF symptoms/events (Obesity Canada 2025, ADA 2026).
- SURMOUNT-1 / SUMMIT / SURMOUNT-OSA: tirzepatide achieves 15–21% weight loss, cuts HFpEF CV death/worsening HF events, and reduces OSA apnoea-hypopnoea index (Obesity Canada 2025).
- LEADER / REWIND: liraglutide (CV death + MACE) and dulaglutide (MACE + stroke) establish cardiorenal protection in T2DM (Diabetes Canada 2024).
Prepared 2026-11-19. Not yet verified — check every number against the sources.